1. Pink Sheet
  2. >>Market Access

Payer Wish List For EU Pharma Legislation – Is The European Commission Listening?

 
• By Francesca Bruce

At a recent webinar payers and health technology appraisal bodies gave further details on what they want included and left out of the European Commission’s overhaul of the EU pharmaceutical legislation. However, speakers voiced some concerns about whether their demands will be met. 

vector illustration of businessman standing on the edge of ravine thinking before making a decision. describe challenge, risk, obstacles, take a risk and danger.
Evidence requirements to support HTA evaluation should not be seen as an extra obstacle • Source: Shutterstock

Payers and health technology appraisal (HTA) bodies are calling for the European Commission’s reform of the EU pharmaceutical legislation to include requirements for providing comparative data but to reject more pandemic-style rolling reviews and transferable exclusivity vouchers. However, there are doubts about whether the commission will take on the suggestions, said speakers at a recent webinar on 13 July.

Payers and HTA bodies gave more details on their wish list for what should be included in the commission’s overhaul of EU pharmaceutical legislation at a recent webinar organized by ESIP, the European Social Insurance Platform, which represents 45 national social security organizations and MEDEV, the Medicine Evaluation Committee, which comprises 22 national HTA authorities. The webinar follows a publication of their recommendations for reform earlier this month

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare?

 
• By Cathy Kelly

President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 
• By Francesca Bruce

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.